Jefferies London Healthcare Conference 2023. Panelists seated left to right: LTS Lohmann CEO Bas van Buijtenen, Axplora CEO Sylke Hassel, and Bachem Holding CEO Thomas Meier (Credit: Reynald Castañeda for Endpoints News)

November 17, 2023 11:08 AM EST

CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23

Anna Brown

News Reporter

If there were two key ideas that sprung from the CDMO panel at this week’s Jefferies London Healthcare Conference, it is that manufacturers are reviewing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23

Anna Brown

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

CD­MOs in­ves­ti­gate how to sup­port GLP-1 man­u­fac­tur­ing, phar­ma con­sid­ers sup­ply chain di­ver­si­ty: #Jef­feries23

Anna Brown

News Reporter

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

CDMOs investigate how to support GLP-1 manufacturing, pharma considers supply chain diversity: #Jefferies23

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?